Fgf16 has been described to prevent cardiac hypertrophy and fibrosis by competing with Fgf2 for the binding site of the FGF receptor 1c, Fgfr1c, in a paracrine manner (Itoh and Ohta 2013). Here, FGF2 is linked to cardiac hypertrophy.